Table 5 Univariate and multivariate analysis for overall survival using Cox relative risk
From: MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer
Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| Â | RR (95% CI) | P value1 | RR (95% CI) | P value1 |
MPC1 expression in tumor | 0.561 | 0.000 | 0.654 | 0.000 |
| Â | (0.536-0.588) | Â | (0.621-0.690) | Â |
MPC2 expression in tumor | 0.558 | 0.000 | 0.696 | 0.000 |
| Â | (0.533-0.585) | Â | (0.660-0.734) | Â |
Age | 0.977 | 0.000 | 0.998 | 0.371 |
(≤71 year vs >71 year) | (0.973-0.981) |  | (0.994-1.002) |  |
UICC stage | 1.34 | 0.000 | 1.198 | 0.000 |
(pT2 vs pT3-pT4) | (1.259-1.427) | Â | (1.095-1.311) | Â |
Gleason score | 1.769 | 0.000 | 1.635 | 0.000 |
(< 7, 7-10 ) | (1.645-1.902) | Â | (1.514-1.765) | Â |
PSA(ng/ml) | 1.344 | 0.000 | 1.091 | 0.000 |
(≤10, > 10 and ≤ 20,> | (1.286-1.405) |  | (1.040-1.143) |  |
lymph node metastasis | 1.361 | 0.000 | 0.985 | 0.742 |
(positive vs negative) | (1.253-1.478) | Â | (0.897-1.080) | Â |
distant metastasis | 1.094 | 0.008 | 1.049 | 0.293 |
(positive vs negative) | (1.023-1.170) | Â | (0.960-1.147) | Â |